Position of the Transparency Council – Trimbow (beclometasone, formoterol, glycopyrronium bromide)
At its meeting on 12 May 2025, the Transparency Council adopted position No. 58/2025 on the appraisal of drug Trimbow (beclometasone, formoterol, glycopyrronium bromide) in the indication: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease